A method to include the environmental hazard in drug prescribing

Pharmacy World and Science

Volumn 31, Issue 1, 2009, Pages 24-31

  Castensson, Staffan ^a   Eriksson, Viktoria ^a   Lindborg, Kristina ^b   Wettermark, Björn ^c,d  

^a National Corporation of Swedish Pharmacies   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM COUNTY COUNCIL   (Sweden)

^d Network for Pharmacoepidemiology Foundation   (Sweden)

Author keywords

Drug prescribing; Drug utilization; Environmental hazard; Sweden

Indexed keywords

ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; DRUG UTILIZATION; ENVIRONMENTAL FACTOR; OUTCOME ASSESSMENT; PHARMACY; PRESCRIPTION;

DRUG UTILIZATION; HAZARDOUS SUBSTANCES; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTION DRUGS; WATER POLLUTANTS, CHEMICAL;

EID: 58149312960     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-008-9260-1     Document Type: Article

References (33)

1. Kümmerer K, editor. Pharmaceuticals in the environment. Sources, fate, effects and risks. 2nd ed. Berlin, Heidelberg, New York: Springer; 2004. ISBN 3-540-21342-2.
2. Apoteket AB (The National Corporation of Swedish Pharmacies), Stockholm County Council, Stockholm University. Environment and pharmaceuticals. Stockholm, Sweden: Apoteket AB; 2006. ISBN 91-85574-55-4. Cited 2008 Jan 18. Available from: http://www2.apoteket.se/NR/rdonlyres/FAB1EBDB-319A-4B45-95DA- CB4D863FE525/0/EnvironmentandPharmaceuticals.pdf.
3. D Ashton M Hilton KV Thomas 2004 Investigating the environmental transport of human pharmaceuticals to streams in the United Kingdom Sci Total Environ 333 167 84 10.1016/j.scitotenv.2004.04.062
4. B Halling-Sørensen S Nors Nielsen PF Lanzky F Ingerslev HC Holten Lützhøft SE Jørgensen 1998 Occurrence, fate and effects of pharmaceutical substances in the environment-a review Chemosphere 36 357 93 10.1016/S0045-6535(97)00354-8
5. A Nikolaou S Meric D Fatta 2007 Occurrence patterns of pharmaceuticals in water and wastewater environments Anal Bioanal Chem 387 1225 34 10.1007/s00216-006-1035-8
6. E Zuccato S Castiglioni R Fanelli G Reitano R Bagnati C Chiabrando F Pomati C Rossetti D Calamari 2006 Pharmaceuticals in the environment in Italy: causes, occurrence, effects and control Environ Sci Pollut Res Int 13 15 21 10.1065/espr2006.01.004
7. DW Kolpin ET Furlong MT Meyer EM Thurman SD Zaugg LB Barber HT Buxton 2002 Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance Environ Sci Technol 36 1202 11 10.1021/es011055j
8. K Kümmerer 2003 Significance of antibiotics in the environment J Antimicrob Chemother 52 5 7 10.1093/jac/dkg293
9. Environmental Objectives Secretariat. Environmental objectives portal. Cited 2008 Jan 21. Available from: http://www.miljomal.nu/english/english.php.
10. Miljöpåverkan från läkemedel samt kosmetiska och hygieniska produkter. Rapport från Läkemedelsverket. Augusti 2004. (Environmental impact of drugs and of cosmetic and hygienic products. Report from Swedish Medical Products Agency. August 2004.) Cited 2008 Jan 21. Available from: http://www.lakemedelsverket.se/upload/Om%20LV/publikationer/ 040824_miljouppdraget-rapport.pdf.
11. B Wettermark B Godman K Andersson LL Gustafsson A Haycox V Bertele 2008 Recent national and regional reforms in Sweden-implications for pharmaceutical companies in Europe Pharmacoeconomics 26 537 50
12. Å Wennmalm B Gunnarsson 2005 Public health care management of water pollution with pharmaceuticals: environmental classification and analysis of pharmaceutical residues in sewage water Drug Inf J 39 291 7
13. Stockholm County Council (homepage on the Internet). About classification. Updated: 2007-07-05; cited 2008 Jan 21. Available from: http://www.janusinfo.se/imcms/servlet/GetDoc?meta_id=7239.
14. Stockholm County Council (homepage on the Internet). Environmentally classified pharmaceuticals. Updated: 2007-12-11; cited 2008 Jan 21. Available from: http://www.janusinfo.se/imcms/servlet/GetDoc?meta_id=7238.
15. LA Bero R Grilli JM Grimshaw E Harvey AD Oxman MA Thomson 1998 Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group BMJ 317 465 8
16. Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess. 2004;8(6):iii-iv, 1-72.
17. B Wettermark A Pehrsson D Jinnerot U Bergman 2003 Drug utilisation 90% profiles-a useful tool for quality assessment of prescribing in primary health care in Stockholm Pharmacoepidemiol Drug Saf 12 499 510 10.1002/pds.852
18. B Wettermark K Haglund LL Gustafsson PM Persson U Bergman 2005 A study of adherence to drug recommendations by providing feedback of outpatient prescribing patterns to hospital specialists Pharmacoepidemiol Drug Saf 14 579 88 10.1002/pds.1098
19. Collaboration WHO. Center for drug statistics methodology (homepage on the Internet). Guidelines for ATC classification and DDD assignment. Oslo; 2007. Cited 2008 Jan 21. Available from: www.whocc.no.
20. Statistics Sweden. Cited 2008 June 27. Available from: http://www.h.scb.se/kommunfakta/pyramider/pyra_frame.asp?region=01.
21. European Chemicals Bureau (ECB). Technical Guidance Document on Risk Assessment in support of Commission Directive 93/67/EEC on Risk Assessment for new notified substances and Commission Regulation (EC) No 1488/94 on Risk Assessment for existing substances and Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market. Part I. EUR 20418 EN/1. Luxembourg; 2003. Cited 2008 Sept 24. Available from: http://ecb.jrc.it/Documents/TECHNICAL_GUIDANCE_DOCUMENT/EDITION_2/ tgdpart1_2ed.pdf.
22. Tyle H, Larsen HS, Wedebye EB, Sijm D, Pedersen Krog T, Niemelä J. Identification of potential PBTs and vPvBs by use of QSARs. Copenhagen; 2002. Cited 2008 Sept 24. Available from: http://ecb.jrc.it/classlab/otherdocs/ QSAR_PBT_final_clean.doc.
23. World Health Organization (WHO). The rational use of drugs. WHO Report of the Conference of Experts, Nairobi. Geneva, Switzerland: World Health Organization; 1985.
24. SL Bronzwaer O Cars U Buchholz S Mölstad W Goettsch IK Veldhuijzen JL Kool MJ Sprenger JE Degener 2002 European antimicrobial resistance surveillance system. A European study on the relationship between antimicrobial use and antimicrobial resistance Emerg Infect Dis 8 278 82
25. Kaplan W, Laing R. Priority medicines for Europe and the world project. A public health approach to innovation. Geneva: WHO; 2004.
26. H Goossens M Ferech R Vander Stichele M Elseviers 2005 Outpatient antibiotic use in Europe and association with resistance: a cross-national database study Lancet 365 579 87
27. D Henry LLY Lim LA Garcia Rodrigues S Perez Gutthann JL Carson M Griffin R Savage R Logan Y Moride C Hawkey S Hill JT Fries 1996 Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analyses BMJ 312 1563 6
28. Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005;2:CD002946.
29. LH Lindholm B Carlberg O Samuelsson 2005 Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis Lancet 366 1545 53 10.1016/S0140-6736(05)67573-3
30. Swedish Council on Technology Assessment in Health Care (SBU). Moderately elevated blood pressure. SBU report 170, 2004. Stockholm; 2004.
31. Swedish Council on Technology Assessment in Health Care (SBU). Treatment of depression. A systematic review. Report number 166 (2 vol). 2004. ISBN 91-87890-88-7.
32. Wettermark B. Drug utilization 90%-using aggregate drug statistics for the quality assessment of prescribing. 2004. ISBN 91-7140-048-6.
33. EMEA. Guideline on the environmental risk assessment of medicinal products for human use EMEA/CHMP/SWP/4447/00. London; 2006. Available from: http://www.emea.europa.eu/pdfs/human/swp/444700en.pdf.